Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sanofi-aventis Licenses New Anti-Diabetic Agent from Wellstat Pharmaceuticals
November 2, 2009
- Price Maintenance System Essential to Make Drug Market in Japan More Attractive: Mr Kinosita
November 2, 2009
- 35 Products Approved Including Januvia/Glactiv -1-
November 2, 2009
- Korosho Increases FY2010 Budget Request to ¥28,889.4 Bil.
November 2, 2009
- Generics Use Rate by Far the Highest in Okinawa Prefecture
November 2, 2009
- Hatoyama Administration to Change Medical Expenditure Curtailment Policy
November 2, 2009
- Kyowa Kirin Transfers Neu-Up to Yakult
November 2, 2009
- Korosho to Issue Guidance for Transmission of Safety Information
November 2, 2009
- Medipal Ties Up with China's Largest Drug Wholesaler
November 2, 2009
- Bridion Recommended for Approval
November 2, 2009
- Terumo's Drug-Saving FN Syringe Approved in 3 Months
November 2, 2009
- 35 Products Approved Including Januvia/Glactiv -2-
November 2, 2009
- JMA to Reconsider Its Relationship with LDP
November 2, 2009
- Mr Hasegawa Appointed Chairman of MLIT's Growth Strategy Council
November 2, 2009
- Korosho to Increase Financial Assistance for IFN Therapy
November 2, 2009
- Top-Five Wholesalers Revise Half-Year Business Forecasts Upward
November 2, 2009
- R&D NEWS IN BRIEF
November 2, 2009
- Eisai Licenses Denileukin Diftitox to TSD Japan
November 2, 2009
- Global Trials Conducted by EFPIA Member Companies Show Sharp Increase
November 2, 2009
- Teijin Sublicenses TMX-67 to Menarini in Europe
November 2, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…